- Home
- ZYBT vs KTTA Comparison
ZYBT vs KTTA Comparison
Compare ZYBT & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- KTTA
- Stock Information
- Founded
- ZYBT 2004
- KTTA 2020
- Country
- ZYBT China
- KTTA United States
- Employees
- ZYBT N/A
- KTTA 4
- Industry
- ZYBT
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- KTTA Health Care
- Exchange
- ZYBT NYSE
- KTTA Nasdaq
- Market Cap
- ZYBT 340.3M
- KTTA 5.5M
- IPO Year
- ZYBT 2025
- KTTA 2021
- Fundamental
- Price
- ZYBT $6.05
- KTTA $0.73
- Analyst Decision
- ZYBT
- KTTA
- Analyst Count
- ZYBT 0
- KTTA 0
- Target Price
- ZYBT N/A
- KTTA N/A
- AVG Volume (30 Days)
- ZYBT 357.1K
- KTTA 166.4K
- Earning Date
- ZYBT 07-03-2025
- KTTA 08-12-2025
- Dividend Yield
- ZYBT N/A
- KTTA N/A
- EPS Growth
- ZYBT N/A
- KTTA N/A
- EPS
- ZYBT 0.06
- KTTA N/A
- Revenue
- ZYBT $26,111,272.00
- KTTA N/A
- Revenue This Year
- ZYBT N/A
- KTTA N/A
- Revenue Next Year
- ZYBT N/A
- KTTA N/A
- P/E Ratio
- ZYBT $98.97
- KTTA N/A
- Revenue Growth
- ZYBT N/A
- KTTA N/A
- 52 Week Low
- ZYBT $3.50
- KTTA $0.70
- 52 Week High
- ZYBT $14.30
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- KTTA 36.47
- Support Level
- ZYBT N/A
- KTTA $0.70
- Resistance Level
- ZYBT N/A
- KTTA $0.76
- Average True Range (ATR)
- ZYBT 0.00
- KTTA 0.04
- MACD
- ZYBT 0.00
- KTTA 0.01
- Stochastic Oscillator
- ZYBT 0.00
- KTTA 21.88
About ZYBT ZHENGYE BIOTECHNOLOGY HLDG LTD
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).